pectins has been researched along with Osteosarcoma* in 2 studies
2 other study(ies) available for pectins and Osteosarcoma
Article | Year |
---|---|
Redox-responsive microbeads containing thiolated pectin-doxorubicin conjugate inhibit tumor growth and metastasis: An in vitro and in vivo study.
The objective of this study was to investigate the in vitro cytotoxicity and in vivo anticancer efficacy of redox-responsive microbeads containing thiolated pectin-doxorubicin (DOX) conjugate. Oral microbeads were coated with an enteric polymer to protect the drug from release in the upper gastrointestinal (GI) tract and allow redox-triggered drug release in the colon. Morphology, particle size, drug content, and in vitro drug release behavior of the microbeads were characterized; in vitro cytotoxicity was tested on mouse colon carcinoma, human colorectal adenocarcinoma, and human bone osteosarcoma cell lines. In vivo anticancer efficacy of coated microbeads was examined in BALB/c mice with murine colon carcinoma. These coated microbeads significantly inhibited the growth of all cell lines. The in vivo study confirmed delivery of DOX to the colorectal tumor site, redox-responsiveness, and anticancer efficacy of coated microbeads. Coated microbeads also effectively inhibited primary tumor growth and suppressed tumor metastases without gross toxicity to the non-target tissue. No noticeable damage was found in mouse GI tissues, indicating lack of DOX toxicity. These novel coated microbeads containing thiolated pectin-DOX conjugate may be a promising vehicle for targeted clinical delivery of DOX to the colorectal cancer site by oral administration. Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Bone Neoplasms; Caco-2 Cells; Cell Proliferation; Colorectal Neoplasms; Delayed-Action Preparations; Doxorubicin; Drug Carriers; Drug Compounding; Drug Liberation; HT29 Cells; Humans; Male; Mice, Inbred BALB C; Osteosarcoma; Oxidation-Reduction; Pectins; Sulfhydryl Compounds; Technology, Pharmaceutical; Time Factors; Tumor Burden | 2018 |
Thiolated pectin-doxorubicin conjugates: Synthesis, characterization and anticancer activity studies.
In this paper, pectin was cross-linked by a coupling reaction with either thioglycolic acid or cystamine dihydrochloride to form thiolated pectins. The thiolated pectins were then coupled with doxorubicin (DOX) derivative to obtain thiolated pectin-DOX conjugates by two different methods, disulfide bond formation and disulfide bond exchange. The disulfide bond exchange method provided a simple, fast, and efficient approach for synthesis of thiolated pectin-DOX conjugates, compared to the disulfide bond formation. Characteristics, physicochemical properties, and morphology of thiolated pectins and thiolated pectin-DOX conjugates were determined. DOX content in thiolated pectin-DOX conjugates using low methoxy pectin was found to be higher than that using high methoxy pectin. The in vitro anticancer activity of thiolated pectin-DOX conjugates was significantly higher than that of free DOX, in mouse colon carcinoma and human bone osteosarcoma cells, but insignificantly different from that of free DOX, in human prostate cancer cells. Due to their promising anticancer activity in mouse colon carcinoma cells, the thiolated pectin-DOX conjugates might be suitable for building drug platform for colorectal cancer-targeted delivery of DOX. Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Cross-Linking Reagents; Doxorubicin; Drug Carriers; Humans; Male; Mice; Osteosarcoma; Pectins; Sulfhydryl Compounds | 2017 |